Opus Genetics Secures Long-Term Financing

Opus Genetics has secured strategic long-term financing from Oberland Capital, reinforcing its leadership in developing gene therapies for inherited retinal diseases. This funding is critical for advancing the company's pipeline and supporting its mission to bring innovative treatments to patients. The investment from Oberland Capital highlights confidence in Opus Genetics' scientific progress and market potential. This financial backing will enable the company to pursue its development goals and solidify its position in the competitive gene therapy landscape.